COMPLETED

Feasibility Trial Using an Inpatient Insulin Dosing Calculator

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this feasibility trial is to test whether a novel insulin dosing calculator can improve blood glucose management for patients with type 2 diabetes mellitus on hospital admission. The main questions it aims to answer are: * Whether using this calculator leads to no excessive hypoglycemia? * Whether using this calculator leads to a decrease of hyperglycemia? Participants will receive initial insulin doses by the calculator on hospital admission, and the rest of care will follow standard of care. Participants will be compared with patients in the UW observational cohort who received initial insulin doses by standard of care.

Official Title

Feasibility Trial Using an Insulin Dosing Calculator for Patients With Type 2 Diabetes Mellitus on Hospital Admission

Quick Facts

Study Start:2024-03-22
Study Completion:2025-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06206525

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients who are admitted to University of Washington Medical Centers
  2. * With history of type 2 and/or steroid-induced diabetes mellitus
  3. * Receiving insulin therapy prior to admission
  1. * Patients who are admitted to ICU or obstetrics ward
  2. * Patients who are admitted for elective surgery or procedure
  3. * Patients who present with diabetic ketone acidosis, hyperosmolar hyperglycemic state or require intravenous insulin infusion
  4. * Patients who have no meal intake for 24 hours prior to admission, or planned nothing per oral (NPO) during the first 24 hours after admission
  5. * Patients who report low appetite (25% or less) on admission or have a significantly decreased level of consciousness that they unlikely eat right after admission
  6. * Patients who receive enteral feeding after admission
  7. * Patients who develop severe acute kidney injury needing dialysis therapy

Contacts and Locations

Principal Investigator

Hou-Hsien Chiang, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Washington

Study Locations (Sites)

Harborview Medical Center
Seattle, Washington, 98104
United States
UW Medical Center - Northwest
Seattle, Washington, 98133
United States
UW Medical Center - Montlake
Seattle, Washington, 98195
United States

Collaborators and Investigators

Sponsor: University of Washington

  • Hou-Hsien Chiang, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Washington

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-22
Study Completion Date2025-05-31

Study Record Updates

Study Start Date2024-03-22
Study Completion Date2025-05-31

Terms related to this study

Additional Relevant MeSH Terms

  • Diabetes Mellitus, Type 2